Cartoon Mascot Masks Nasty Health Care Feud
Californiaās health insurers trotted out a heart-healthy character with an ulterior motive ā taking a dig at drugmakers.
Drug Costs
541 - 560 of 698 Results
-
-
In An Effort To Curb Drug Costs, States Advance Bills To Prod Feds On Importation
Legislatures in blue and red states alike are considering proposals that would allow them to import prescription drugs from Canada.
-
FDA Head Vows To Tackle High Drug Prices And Drugmakers āGaming The Systemā
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what heās doing to spur competition and bring down drug prices.
By Sarah Jane Tribble and Liz Szabo -
Trump’s Budget Proposal Swings At Drug Prices With A Glancing Blow
The Trump administration rolled out a list of actions to attack drug prices, but most dance around the edges.
-
KHN On NPR: The Uniquely American Problem Of High Prescription Drug Costs
Kaiser Health News Editor-in-Chief Elisabeth Rosenthal discusses drug costs with Scott Simon, the host of NPR's Weekend Edition. Listen to the broadcast and read a transcript of that conversation.
-
Podcast: KHNās āWhat The Health?ā Thereās A Really Big Health Bill In That Budget Deal
In this episode of KHNās āWhat the Health?ā Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Joanne Kenen of Politico and Margot Sanger-Katz of The New York Times discuss the health policy changes included in the just-concluded bipartisan budget deal on Capitol Hill. The panelists also talk about the final enrollment numbers for individual insurance purchased under the Affordable Care Act, and possible drug price proposals in President Donald Trumpās upcoming budget. Plus, Rovner interviews Andy Slavitt, who this week launched a health care advocacy group called āThe United States of Care.ā
-
As States Target High Drug Prices, Pharma Targets State Lawmakers
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits.
By Jay Hancock and Shefali Luthra -
Podcast: KHN’s āWhat The Health?ā The State Of The (Health) Union
In this episode of KHNās āWhat the Health?ā Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo and Julie Appleby and Sarah Jane Tribble of Kaiser Health News discuss President Donald Trumpās promises to reduce drug prices in his first State of the Union Address. The panelists also discuss the departure of the director of the Centers for Disease Control and Prevention after conflict-of-interest reports and the efforts by some states to flout the Affordable Care Act.
-
Expert Advice For The Corporate Titans Taking On Health Care
Amazon, Berkshire Hathaway and JPMorgan Chase & Co. are partnering up to address employee health care costs and improve satisfaction. Can they deliver? And would repackaging health insurance involve drones?
-
States Face Costly Conundrum: How To Treat Inmates With Hepatitis C
Although the potentially fatal disease isĀ common among the incarcerated, treatment with the latest hepatitis drugs isn't.
-
Podcast: What The Health? Our First Live Show: What The Health Will Happen In 2018?
In this episode of āWhat The Health?ā ā taped before a live audience ā panelists discuss the potential federal government shutdown and what may be in store for health in 2018. They are joined by former Medicare and Medicaid head Tom Scully.
-
Fallout From ‘Nuclear Buttonā Tweets: Sales Of Anti-Radiation Drug Skyrocket
Orders for potassium iodide reportedly jumped after a Jan. 2 war of words between Trump and North Koreaās Kim Jong-un.
-
Facebook Live: Itās 2018, Can Big Pharma Hold The Line Against Pricing Controls?
In this chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industryās agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.
-
HHS Nominee Vows To Tackle High Drug Costs, Despite His Ties To Industry
Alex M. Azar II, the former president of the U.S. division of Eli Lilly, says the U.S. drug system encourages price increases ā but he intends to work on that problem.
-
From Retirement To The Front Lines Of Hepatitis C Treatment
This doctor came out of retirement with the goal of treating every patient at high risk for hepatitis C he encounters. The problem is finding them.
-
Readers Have Bones To Pick, From Health System Flaws To Covering Pot Beat
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
FDA Chief Says Heās Open To Rethinking Incentives On Orphan Drugs
The FDAās Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
-
Arthritis Drugs Show How U.S. Drug Prices Defy Economics
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
-
Biosimilars, Biologics And New Legal Challenges For RA Treatments
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.
-
Drug Industry Spent Millions To Squelch Talk About High Drug Prices
Last year, the pharma industryā biggest trade group raised millions to change the conversation about drug pricing.
By Jay Hancock